Characteristics of Patients Co-infected with Severe Acute Respiratory Syndrome Coronavirus 2 and Dengue Virus, Buenos Aires, Argentina, March–June 2020

Abstract

S evere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which produces coronavirus disease (COVID-19), and dengue caused an epidemic in Argentina during 2020. During March 3-October 25, 2020, a total of 1,090,589 confirmed cases of infection with SARS-CoV-2 were reported in this country. Of these cases, 143,990 were reported in Ciudad Autónoma de Buenos Aires (1). During January 4-June 13, 2020, there were ≈7,300 confirmed cases of dengue virus infection in this city (2). Although co-infection with these 2 virus is a major concern, it has only been reported in individual patients (3-5). Information from cohorts of co-infected patients is still lacking. We describe the clinical characteristics and outcomes in a cohort of patients co-infected with SARS-CoV-2 and dengue virus in Buenos Aires. Methods Using a network of colleagues (COVIDENGUE Study Group), we retrospectively identified patients coinfected with SARS-CoV-2 and dengue virus during March-June 2020. Seven sites were in Buenos Aires, and an additional site was in the surrounding area. Through June 30, 2020, healthcare admission was mandated in Argentina for any patient with confirmed COVID-19. Therefore, all patients had complete information regarding signs and symptoms at hospitalization, as well as their hospital course. Clinical data were obtained in a predesigned clinical report form by reviewing medical records. Infection with SARS-CoV-2 was diagnosed by using real-time PCR of nasopharyngeal swab specimens, as approved by the Ministry of Health in reference laboratories. Dengue was diagnosed by either detec

Characteristics of patients coinfected with Severe Acute Respiratory Syndrome Coronavirus 2 and dengue virus, Lambayeque, Peru, May–August 2020: A retrospective analysis

“…Dengue and COVID-19 share clinical findings, such as fever, myalgia, fatigue, headache, rash [ 12 ], and laboratory findings, making, in endemic areas or in travellers coming from, difficult to distinguish between both conditions. Additionally, as expected, coinfections COVID-19/Dengue have been reported in different countries, such as Mayotte (Indian ocean) [ 13 ], La Reunión (Indian ocean) [ 14 ], Argentina [ [15] , [16] , [17] ], Colombia [ 18 ], among others.…”

SARS-CoV-2 and Dengue virus co-infection: A case from North Caribbean Colombia

“…Now, concurrent overlapping infections have increasingly been reported from Brazil, Ecuador, Colombia and Peru [ 1 , 2 ]. Furthermore, occurrence of co-infections in Mayotte, Argentina and other places [ 3 , 4 ] have been reported, including many of them in returning travelers. Herein, we report a case of COVID-19 and Dengue co-infection in Colombia and discuss the potential clinical and epidemiological challenges of current syndemics.…”

“…This case report highlights the complexity in the distinction between the shared clinical features of dengue and COVID-19, including their dermatological manifestations [ [1] , [2] , [3] , [4] ]. Up to May 24 th , 2021, Colombia had reported 3,249,433 COVID-19 cases, with 85,207 deaths (2.62%).…”

“…To date, little has been published on how SARS-CoV-2 and DENV coinfection may influence clinical outcomes. A recent study from Carosella et al suggests that co-infection by these viruses does not lead to worsening symptoms when compared to SARS-CoV-2 or DENV infections alone [ 4 ]. Such findings may be explained in part by the opposed pro and anticoagulant states triggered by SARS-CoV-2 and DENV respectively, as well as to other potential causes such as viral interference [ 5 ].…”

“…Moreover, computational docking studies have shown that human DENV antibodies can bind to the receptor-binding (RBD) domain of SARS-CoV-2 spike protein conferring some degree of protection leading to reduced disease severity [ 6 ]. In addition, experimental evidence suggesting that blockage of AT1 and inhibition of ACE receptor may lead to decreased DENV cell internalization [ [4] , [5] , [6] ] provides further insights on how interaction between these two viruses may modulate disease outcome. Further studies aimed to provide a better understanding on how viral interaction and pathogenic mechanisms amongst these viruses modulate disease are urgently needed to better define disease prognosis in DENV and other arboviral endemic areas.…”